Zárate A, Hernández M, Basurto L

Language: Spanish
References: 16
Page: 14-17
PDF size: 47.03 Kb.

ABSTRACT

Analysis of the literature regarding the risk/benefit ratio on hormone replacement therapy (HRT) in the menopause has suggested: 1) relative risk (RR) for breast cancer and coronary heart disease is considered low, 2) high RR for thromboembolism and stroke, and 3) some protective effect for femur fracture and colon cancer. On basis of these data it has been recommended that HRT should not be used for primary or secondary prevention of coronary ischemia, and that use of HRT be based on the particular analysis of each person; therefore the risk/benefit rate should be determined individually.

REFERENCES

1. Writing Group for the Women´s Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women´s Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.

2. Beral V, Banks E, Reeves G. Evidence from randomized trials on the long-term effects of hormone replacement therapy. Lancet 2002; 360: 942-944.

3. Grady D. Postmenopausal hormones – Therapy for symptoms only. N Engl J Med 2003; 348: 19-21.

4. Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA, for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 2002; 287: 591-597.

5. Breslau ES, Davis WW, Doner L, Eisner EJ, Goodman NR, Meissner HI, Rimer BK, Rossouw JE. The Hormone Therapy Dilemma: Women Respond. JAMA 2003; 58: 32-43.

6. Zárate A, Hernández-Valencia M. Terapia de reemplazo hormonal en mujeres menopáusicas tratadas por cáncer mamario. Rev Med IMSS 2002; 40: 369-371.

7. Shapiro M. Menopause: Current controversies in hormone replacement treatment. Geriatrics Aging 2003; 6: 30-33.

8. Simon JA, Hsia J, Cauley JA. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001; 103: 638-642.

9. O’Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001; 93: 754-761.

10. Herrington DM, Vittinghoff E, Lin F, for the HERS Study Group. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 2002; 105: 2962-2967.

11. Hsia J, Simon JA, Lin F. Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease: the Heart and Estrogen/Progestin Replacement Study. Circulation 2000; 102: 2228-2232.

12. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001; 345: 1243-1249.

13. Basurto L, Saucedo R, Ochoa R, Hernández-Valencia M, Zárate A. La terapia de reemplazo hormonal con estradiol transdérmico disminuye los niveles de insulina-cortisol y lipoproteínas en mujeres posmenopáusicas. Ginec Obstet Mex 2002; 70: 491-495.

14. Hernández-Valencia M, Fonseca ME, Ochoa R, Zárate A. Efectos metabólicos en la menopausia de un esteroide sintético (tibolona) con acción estrogénica característica. Ginec Obstet Mex 1997; 65: 145-147.

15. Mead TW, Vickers MR. HRT in cardiovascular disease. J Epidemiol Biostat 1999; 4: 165-90.

16. Fiorica JV. The Breast. In: Scott JR, Di Saia PJ, Hammond CB, Spellacy WN. Obstetrics & Gynecology. 8th Ed, Lippincott, Phi, 2000: 631.